ADXN
Addex Therapeutics Ltd
Biotechnology
Market Cap$5M
5Y Perf.-96.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ADXN vs SAVA vs ACAD vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.+94.9%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.84B
5Y Perf.-51.8%
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.53B
5Y Perf.-37.1%
ADXN vs SAVA vs ACAD vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ADXN | SAVA | ACAD | PRAX |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $5M | $94M | $3.84B | $9.53B |
| Revenue (TTM) | $68K | $0.00 | $1.10B | $0.00 |
| Net Income (TTM) | $-6M | $-106M | $376M | $-327M |
| Gross Margin | -246.8% | — | 91.5% | — |
| Operating Margin | -36.7% | — | 7.4% | — |
| Forward P/E | 0.6x | — | 55.6x | — |
| Total Debt | $42K | $0.00 | $52M | $110K |
| Cash & Equiv. | $3M | $129M | $178M | $357M |
ADXN vs SAVA vs ACAD vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ADXN
SAVA
ACAD
PRAX
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Addex Therapeutics … (ADXN) | 100 | 3.1 | -96.9% |
| Cassava Sciences, I… (SAVA) | 100 | 194.9 | +94.9% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 48.2 | -51.8% |
| Praxis Precision Me… (PRAX) | 100 | 62.9 | -37.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADXN vs SAVA vs ACAD vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Addex Therapeutics Ltd is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. PRAX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ADXN
Addex Therapeutics Ltd
The Income Pick
ADXN is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.60
- Lower volatility, beta 0.60, Low D/E 0.4%, current ratio 4.42x
- Beta 0.60, current ratio 4.42x
- Better valuation composite
Best for: income & stability and sleep-well-at-night
SAVA
Cassava Sciences, Inc.
The Long-Run Compounder
SAVA is the clearest fit if your priority is long-term compounding.
- -19.5% 10Y total return vs PRAX's -20.9%
Best for: long-term compounding
ACAD
ACADIA Pharmaceuticals Inc.
The Growth Play
ACAD carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- 11.9% revenue growth vs SAVA's -5.4%
- 34.3% margin vs ADXN's -90.2%
- 26.2% ROA vs SAVA's -75.3%, ROIC 10.0% vs -6.3%
Best for: growth exposure
PRAX
Praxis Precision Medicines, Inc.
The Momentum Pick
PRAX is the clearest fit if your priority is momentum.
- +7.7% vs ADXN's -13.4%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ACAD | 11.9% revenue growth vs SAVA's -5.4% |
| Value | ADXN | Better valuation composite |
| Quality / Margins | ACAD | 34.3% margin vs ADXN's -90.2% |
| Stability / Safety | ADXN | Beta 0.60 vs SAVA's 1.99 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs ADXN's -13.4% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs SAVA's -75.3%, ROIC 10.0% vs -6.3% |
ADXN vs SAVA vs ACAD vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
FY 2018
FY 2024
ADXN vs SAVA vs ACAD vs PRAX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGSAVA
Who Leads Where
ACAD leads in 2 of 6 categories
PRAX leads 1 • ADXN leads 0 • SAVA leads 0 • 2 tied
Explore the data ↓SAVACassava Sciences, Inc.
0leads
ADXNAddex Therapeutics Ltd
0leads
PRAXPraxis Precision Medi…
1leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs PRAXvs ADXNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and PRAX operate at a comparable scale, with $1.1B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to ADXN's -90.2%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ADXNAddex Therapeutic… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| RevenueTrailing 12 months | $67,607 | $0 | $1.1B | $0 |
| EBITDAEarnings before interest/tax | -$2M | -$110M | $96M | -$357M |
| Net IncomeAfter-tax profit | -$6M | -$106M | $376M | -$327M |
| Free Cash FlowCash after capex | -$2M | -$84M | $212M | -$283M |
| Gross MarginGross profit ÷ Revenue | -2.5% | — | +91.5% | — |
| Operating MarginEBIT ÷ Revenue | -36.7% | — | +7.4% | — |
| Net MarginNet income ÷ Revenue | -90.2% | — | +34.3% | — |
| FCF MarginFCF ÷ Revenue | -23.3% | — | +19.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -44.8% | — | +9.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +11.2% | +62.1% | -81.8% | +2.7% |
ACAD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ADXN and ACAD and PRAX each lead in 1 of 3 comparable metrics.
Valuation Metrics
At 0.6x trailing earnings, ADXN trades at a 94% valuation discount to ACAD's 9.8x P/E.
| Metric | ADXNAddex Therapeutic… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Market CapShares × price | $5M | $94M | $3.8B | $9.5B |
| Enterprise ValueMkt cap + debt − cash | $287,137 | -$34M | $3.7B | $9.2B |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | -3.76x | 9.78x | -24.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 55.62x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 26.71x | — |
| Price / SalesMarket cap ÷ Revenue | 8.72x | — | 3.58x | — |
| Price / BookPrice ÷ Book value/share | 0.45x | 0.63x | 3.13x | 8.46x |
| Price / FCFMarket cap ÷ FCF | — | — | 36.48x | — |
Evenly matched — ADXN and ACAD and PRAX each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-96 for SAVA. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACAD's 0.04x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs SAVA's 2/9, reflecting solid financial health.
| Metric | ADXNAddex Therapeutic… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -78.3% | -95.8% | +35.6% | -43.0% |
| ROA (TTM)Return on assets | -67.7% | -75.3% | +26.2% | -40.2% |
| ROICReturn on invested capital | -103.3% | -6.3% | +10.0% | -65.0% |
| ROCEReturn on capital employed | -47.4% | -99.9% | +10.1% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.00x | — | 0.04x | 0.00x |
| Net DebtTotal debt minus cash | -$3M | -$129M | -$126M | -$357M |
| Cash & Equiv.Liquid assets | $3M | $129M | $178M | $357M |
| Total DebtShort + long-term debt | $41,994 | $0 | $52M | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | -1857.72x | — | — | — |
ACAD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,657 today (with dividends reinvested), compared to $345 for ADXN. Over the past 12 months, PRAX leads with a +767.1% total return vs ADXN's -13.4%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.0% vs ADXN's -22.3% — a key indicator of consistent wealth creation.
| Metric | ADXNAddex Therapeutic… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.5% | -6.5% | -14.3% | +15.2% |
| 1-Year ReturnPast 12 months | -13.4% | +15.0% | +32.3% | +767.1% |
| 3-Year ReturnCumulative with dividends | -53.2% | -40.8% | +3.9% | +1956.2% |
| 5-Year ReturnCumulative with dividends | -96.5% | -64.6% | +6.6% | -14.9% |
| 10-Year ReturnCumulative with dividends | -97.0% | -19.5% | -23.4% | -20.9% |
| CAGR (3Y)Annualised 3-year return | -22.3% | -16.0% | +1.3% | +174.0% |
PRAX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ADXN and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADXN is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than SAVA's 1.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 92.7% from its 52-week high vs SAVA's 39.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADXNAddex Therapeutic… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.60x | 1.99x | 1.11x | 1.40x |
| 52-Week HighHighest price in past year | $12.05 | $4.98 | $27.81 | $356.00 |
| 52-Week LowLowest price in past year | $5.41 | $1.54 | $14.68 | $35.21 |
| % of 52W HighCurrent price vs 52-week peak | +56.8% | +39.3% | +80.5% | +92.7% |
| RSI (14)Momentum oscillator 0–100 | 53.8 | 46.8 | 53.8 | 53.3 |
| Avg Volume (50D)Average daily shares traded | 4K | 727K | 1.7M | 376K |
Evenly matched — ADXN and PRAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SAVA as "Buy", ACAD as "Buy", PRAX as "Buy". Consensus price targets imply 66.3% upside for PRAX (target: $549) vs 55.3% for ACAD (target: $35).
| Metric | ADXNAddex Therapeutic… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $34.78 | $548.80 |
| # AnalystsCovering analysts | — | 12 | 37 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRAX leads in 1 (Total Returns). 2 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
ADXN vs SAVA vs ACAD vs PRAX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ADXN or SAVA or ACAD or PRAX a better buy right now?
For growth investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Addex Therapeutics Ltd (ADXN) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate Cassava Sciences, Inc. (SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ADXN or SAVA or ACAD or PRAX?
On trailing P/E, Addex Therapeutics Ltd (ADXN) is the cheapest at 0.
6x versus ACADIA Pharmaceuticals Inc. at 9. 8x.
03Which is the better long-term investment — ADXN or SAVA or ACAD or PRAX?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +6. 6%, compared to -96. 5% for Addex Therapeutics Ltd (ADXN). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus ADXN's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ADXN or SAVA or ACAD or PRAX?
By beta (market sensitivity over 5 years), Addex Therapeutics Ltd (ADXN) is the lower-risk stock at 0.
60β versus Cassava Sciences, Inc. 's 1. 99β — meaning SAVA is approximately 232% more volatile than ADXN relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ADXN or SAVA or ACAD or PRAX?
By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.
(ACAD) is pulling ahead at 11. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Addex Therapeutics Ltd grew EPS 150. 0% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ADXN or SAVA or ACAD or PRAX?
Addex Therapeutics Ltd (ADXN) is the more profitable company, earning 1746% net margin versus 0.
0% for Praxis Precision Medicines, Inc. — meaning it keeps 1746% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -681. 8% for ADXN. At the gross margin level — before operating expenses — ADXN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ADXN or SAVA or ACAD or PRAX more undervalued right now?
Analyst consensus price targets imply the most upside for PRAX: 66.
3% to $548. 80.
08Which pays a better dividend — ADXN or SAVA or ACAD or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ADXN or SAVA or ACAD or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Addex Therapeutics Ltd (ADXN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
60)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADXN: -97. 0%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ADXN and SAVA and ACAD and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ADXN is a small-cap deep-value stock; SAVA is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; PRAX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.